PEG vs RXRX · P/E 18, rev $10.29B vs rev $58.8M
Public Service Enterprise Group Inc (PEG) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
Public Service Enterprise Group Inc (PEG) is a utilities - regulated electric company listed on NYSE.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported PEG revenue for 2024-12-31 was $10.29B. Net income was $1.77B. Revenue was down 8.4% from 2023-12-31 to 2024-12-31. PEG currently screens at market cap $39.57B and trailing P/E 17.6.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
PEG currently screens at market cap $39.57B and trailing P/E 17.6. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the PEG and RXRX stock pages for the full models.
Not investment advice.